ICER Mixes Up Priorities in Asthma Drug Review
ICER’s priorities differ from severe asthma patients’, and the economists’ approach could make it harder for patients to access the treatment they need. View Infographic
Comments on ICER’s Draft Evidence Report on Tezepelumab for Severe Asthma
Just as asthma impacts people differently, existing treatment options serve some patients better than others.
